ZIM to expand its refrigerated container fleet
The expansion of the refrigerated container fleet will support the growing demand for ZIMonitor, ZIM's premium reefer cargo tracking service.
ZIM Integrated Shipping Services has announced the expansion of its refrigerated container fleet to answer the demand for its innovative ZIMonitor service. Launched in early 2015, ZIMonitor allows customers to track, monitor and remotely control sensitive, high-value cargo stowed in refrigerated, or reefer, containers. Customers can opt to receive alerts regarding their shipment via text message or email, closely monitor their cargo's status and intervene to prevent damages through ZIM's 24/7 dedicated global response team.
An order of approximately 1,900x40-Feet High-Cube refrigerated containers is planned to be deployed during 2016. The new advanced and environmentally friendly containers were specifically designed to accommodate the ZIMonitor service and received a special prefix: ZMOU.
ZIM has partnered with Teva Pharmaceutical Industries, a leading global pharmaceutical company, on a successful pilot of the ZIMonitor service that addressed Teva's uncompromising commitment to the quality of its products and its dedication to meet the requirements of its customers. Upon the successful completion of the pilot, the ZIMonitor service quickly gained popularity among ZIM's customer base.
Nissim Yochai, ZIM's VP of Global Sales stated: "We are very pleased with the growing demand for our monitored services. The ZIMonitor system was designed by ZIM for the cold supply chain and employs state-of-the-art technology. The service provides a tailored solution for customers who ship pharmaceuticals, perishable food and other high-value and sensitive cargo. As part of ZIM's comprehensive strategy, we are committed to further enhance and improve our services in response to what the market needs."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance